Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AMRI | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AMRI

Contract revenue up 16% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI

3Q Revenues: $60.8 million (+9%)

3Q Earnings: $3.9 million (loss of $2.1 million 3Q12)

YTD Revenues: $179.5 million (+13%)

YTD Earnings: $8.2 million (loss of $5.7 million YTD12)

Comments: Total contract revenue in the quarter was $53.0 million, up 16% and includes AMRI’s Discovery Services ($10.4 million, +17%), Development and Small Scale Manufacturing ($9.0 million, +22%), and Large Scale Manufacturing ($33.6 million, +15%). Royalty revenue in the quarter was $7.7 million, down 18% and includes royalties from Allegra products, as well as $2.0 million from certain amphetamine salts sold by Actavis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters